EU approval for Relenza

9th September 2006

GlaxoSmithKline has received approval by European Union regulators for the use of Relenza in 15 countries for the prevention of types A and B influenza.

Having previously been licensed just for use in adults and children aged 12 and over Relenza has also now been approved for the prevention of flu in children aged five and over in the European Union. European governments can now consider the drug for stockpiling in the event of a flu pandemic.